From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective
Paediatrics
Adults
Advate®
30%
24%
Kogenate®
29%
23%
Refacto®
18%
Helixate®
17%
13%
Recombinate®
1%
Plasma-derived products
–
21%